MAP2K7 and melanoma: Results from the DREAMSeq clinical trial determined that the best improvements in PFS and OS were in BRAF V600 mutation-positive melanoma patients receiving a combination of BRAF and MEK inhibitors (dabrafenib/trametinib) (Fig. 3c, Supplementary Table 2).